Securities Litigation Partner James (Josh) Wilson
Encourages Investors Who Suffered Losses Exceeding $50,000 In Revance
Therapeutics To Contact Him Directly To Discuss Their Options
NEW YORK - 
(NewMediaWire) - November 24, 2021 - Faruqi & Faruqi, LLP, a
leading national securities law firm, is investigating potential claims against
Revance Therapeutics, Inc. (“Revance Therapeutics” or the “Company”) (NASDAQ:
RVNC).
If
you suffered losses exceeding $50,000 investing in Revance Therapeutics stock
or options and would like to discuss your legal rights, call Faruqi &
Faruqi partner Josh Wilson directly at 877-247-4292
or 212-983-9330 (Ext. 1310). You may also click
here for additional information: http://www.faruqilaw.com/RVNC.
There
is no cost or obligation to you.
Faruqi & Faruqi is a leading minority
and Woman-owned national securities law firm with offices in New York,
Pennsylvania, California and Georgia.
On October 15, 2021, the U.S. Food and Drug
Administration (FDA) issued a complete response letter (CRL) to Revance
Therapeutics, Inc., citing deficiencies found during an inspection at the
Company's manufacturing facility for its wrinkle injection treatment,
DaxibotulinumtoxinA, or DAXI (a competing product to BOTOX). Shares fell over
30% in after hours trading on October 15, 2021 following news of the FDA
letter. Previously, shares of Revance Therapeutics fell over 25% in intraday
trading on October 12, 2021 after Form 483 was posted to the FDA's website.
Attorney Advertising. The law firm responsible for this
advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a
similar outcome with respect to any future matter. We welcome the opportunity to discuss your
particular case. All communications will
be treated in a confidential manner.
View the original release on www.newmediawire.com
